He graduated from Heriot Watt University in Marine Biology and gained a PhD from the University College of North Wales.

Keith has worked in pharmaceutical development at Covance, Global Head of Life Sciences at PA Consulting Group and Head of Life Sciences Equity Research at Lazard & Co.

He joined finnCap in 2007 with a mandate to build its Life Science franchise and by 2015 it became the largest in the sector on AIM.

Keith retired from his role in finnCap in April 2016.

His experience includes drug development at Eli Lilly and healthcare investment banking with Barclays de Zoete Wedd and JPMorgan.

He worked on major transactions including the IPO of Zeneca and the Wellcome £2.3bn stock offering.

Guy later became Chief Executive of Cancer Research Ventures and Chairman of Cambridge Cognition Ltd.

He has also served as Chief Executive of Deontics Ltd and Trustee of the Royal Society of Medicine.

He holds an MBA from INSEAD.

In recent years he has supported growing healthcare companies through a variety of non-executive roles.

His expertise focuses on helping companies raise investment, build high-performing teams and commercialise successfully.

John advises on the successful integration of cognitive testing into therapeutic development programs.

He is also an Associate Professor with the AUmc Alzheimer Center and Visiting Professor at King’s College London.

He holds Chartered Psychologist status and has authored/co-authored more than 80 books and scientific articles.

His publications include the neuroscience book ‘Synaesthesia: The Strangest Thing’.

Terry is the Co-founder and CEO of LiDCO Group PLC.

Over the last seven years, he has provided consultancy advice to early-stage medical technology companies.

His expertise includes commercialisation and go-to-market strategy for healthcare technologies.

He holds a Ph.D. in Stem Cell Transplantation from Westminster Medical School and a Bachelor's in Human Biology from Surrey University.

Richard is a specialist in Parkinson’s disease and healthcare of the elderly at Northumbria NHS Foundation Trust.

He serves as Clinical Lead for the Northumbria PD Service and Director of R&D for the Trust.

He is closely involved with the DeNDRoN Research Network both locally and nationally.

His main research interests include Parkinson’s disease in the UK and stroke research in Sub-Saharan Africa and Tanzania.

His research focuses on understanding motor function and impairment in diagnosis and treatment.

He specialises in movement disorders including tremor, dyskinesia and bradykinesia.

Prof Caligiuri has contributed significantly to differentiating degenerative disorders from medication-induced disorders.

His work has also demonstrated how antipsychotics and mood stabilizers can normalize cortical and subcortical hyperactivity in bipolar disorder.

John has a passion in his professional life for working with physicians to improve healthcare outcomes. As a person living with Parkinson’s disease, John’s focus has shifted to how he can help improve the lives of persons living with Parkinson’s Disease and help researchers better understand the progression of Parkinson’s Disease by participating in several clinical studies for both REM Sleep Behavior Disorder and Parkinson’s Disease.

John’s leadership spans community, state and national levels — from chairing Moving Day Richmond and the Volunteer Leadership Summit to representing Virginia at the Parkinson’s Policy Forum. Through the People with Parkinson's Advisory Council, he has advised on PD GENEration: Powered by the Parkinson’s Foundation, reviewed community grants and encouraged young investigators at the research grantee summit, demonstrating his commitment to advancing science and care.

Beyond his formal roles, John consistently uses his voice to raise awareness of REM sleep behavior disorder and the lived experience of Parkinson's through local and national media. He partners with healthcare providers at Virginia Commonwealth University, a Parkinson’s Foundation Center of Excellence and beyond — including researchers at Mass General and Harvard — to advance the Foundation's mission. John believes in empowering others through education and has spoken at major events, including the Planning for Prevention of Parkinson's conference and World Parkinson's Congress

https://www.parkinson.org/living-with-parkinsons/stories/john-poma

Her research investigates the neurophysiologic features of movement disorders recorded during deep brain stimulation (DBS), the application of wearables and digital health technologies, and health outcomes research.

Dr. Jimenez-Shahed is Co-Chair of the Executive Committee of the Parkinson Study Group (PSG), where she previously served as Chair of the Mentorship Committee and of the Functional Neurosurgical Working Group. She currently serves as co-chair of the Medical Advisory Board of the Tourette Association of America, on the Board of the International Association of Parkinsonism and Related Disorders, and on the Council of the Deep Brain Stimulation Society. She recently completed a term as Chair of the Science Advisory Board of the Davis Phinney Foundation for Parkinson's and previously chaired the Medical Advisory Board for the Houston Area Parkinson Society.

Dr. Jimenez-Shahed is the recipient of the Roy H. Cullen Quality of Life Award (Houston Area Parkinson Society), the Rising Star Clinician Award (BCM), the Fulbright & Jaworski L.L.P. Faculty Excellence Award in Teaching and Evaluation (BCM) and the Healthcare Heroes Award for Outstanding Health Care Practitioner (Houston Business Journal). She was recognized as a Woman of Excellence at BCM and is a 2018 graduate of the inaugural Women Leading in Neurology program of the American Academy of Neurology.

He studied psychology and neuroscience at the University of Pittsburgh and earned his doctorate in clinical psychology through San Diego State University and the University of California, San Diego. He completed clinical internship and postdoctoral training at MUSC and the VAMC in Charleston.

He provides clinical neuropsychological evaluations for patients followed within movement disorders and is instructor for clinical assessments. His research program is focused on developing new ways to measure and treat cognitive deficits in Parkinson's disease. Current efforts in this pursuit include development and standardization of computerized behavioral saccade tests, neuropsychological assessment, videoconferencing assessments (i.e. telemedicine), and clinical trials (e.g. phospholipid-bound omega-3 supplementation.)

Travis is actively engaged with the Parkinson’s Foundation, Parkinson’s Study Group and M J Fox Foundation.

Evive Health developed a digital communications and engagement platform that enabled health plans, benefit administrators and employers optimize the benefits, resources and programs they offered employees.

Evive’s data-driven personalization was driven by the power of predictive analytics and behavioral science. Evive was backed by Susquehanna Private Equity in 2017. Prashant served as CEO, president and ultimately Chair of the Board at Evive Health until its acquistion by bSwift in October 2025.

Prior to founding Evive Health, Prashant directed clinical operations for Focused Health Solutions amd also commercialized new pharmaceuticals at Pfizer Inc. . Dr. Srivastava earned an MBA from the University of Chicago (GSB’05) and a Ph.D. in Chemical Engineering from Michigan State University.

Michele is Honorary Consultant Neurologist at Oxford University Hospitals.

She is Co-Principal Investigator of the Oxford Parkinson’s Disease Centre.

Her research focuses on biomarkers and early pathological pathways in Parkinson’s disease.

Michele’s interests include wearable technology, sleep-related neurodegeneration research and imaging the human brain.